ComplianceOnline

Glenmark Generics and Konec Inc. to Stop Marketing Unapproved Nitroglycerin Tablets

  • Date: March 16, 2010
  • Source: Admin
Webinar All Access Pass Subscription Abstract:

FDA has ordered Glenmark Generics of Mahwah, N.J., and Konec Inc. of Tucson, Ariz., to stop marketing unapproved nitroglycerin tablets.  FDA has already issued warning letters against these two companies requiring them to remove the unapproved tablets as part of the FDA's Unapproved Drugs Initiative1. Initiative 1 was announced in 2006 in order to address drugs that had not received FDA approval yet being marketed.

Bookmark and Share

Trending Compliance Trainings

Challenges of an Effective Change Control Program
By - Kenneth Christie
On Demand Access Anytime
Implementation and Management of GMP Data Integrity
By - Danielle DeLucy
On Demand Access Anytime
FDA Compliance and Clinical Trial Computer System Validation
By - Carolyn Troiano
On Demand Access Anytime
Biocompatibility Testing; what you need to know
By - Mike Colvin
On Demand Access Anytime
Best Sellers
You Recently Viewed
    Loading